1039 / 1983
Neoadjuvant chemoradiation in esophageal cancer: CROSS trial
Van Hagen et al. NEJM 2012
Shapiro et al. Lancet Oncol 2015
N=363
T1N1M0
or
T2-3N0-1M0
AC (75%)
SCC (23%)
Neo-adjuvant chemoradiotherapy:
41.4 Gy +
weekly Carboplatin AUC2 / Paclitaxel 50 mg/m
2
RESECTION
RESECTION
Primary endpoint: Overall survival
R
A
N
D
O
M
EBRO
2017